CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Economic turmoil in Europe driving the demand for biosimilar
4.1.2. Favourable intervention from the developing economies
4.1.3. Lower cost biosimilar drugs than original biologics
4.1.4. High prevalence of chronic diseases among the ageing population
4.2. Market Restraints & Challenges
4.2.1. High initial investment in research and development
4.2.2. Stringent regulatory requirements to adversely affect investments in biosimilar
4.3. Market Opportunities
4.3.1. opportunities in emerging economies
4.3.2. The emergence of bio-better drugs
CHAPTER 5. GLOBAL BIOSIMILARS MARKET – BY PRODUCT
5.1. Introduction
5.2. Recombinant glycosylated proteins
5.2.1. Insulin
5.2.2. Interferons
5.2.3. Recombinant human growth hormone (RHGH)
5.2.4. Granulocyte colony-stimulating factor (filgrastim)
5.2.4.1. Interferon-beta
5.2.4.2. Interferon-alpha
5.3. Recombinant peptides
5.3.1. Monoclonal antibodies (MABS)
5.3.2. Erythropoietin (EPO)
5.3.2.1. Rituximab
5.3.2.2. Infliximab
5.3.2.3. Adalimumab
5.3.2.4. Other monoclonal antibodies
5.3.3. Follitropin
5.4. Recombinant non-glycosylated proteins
5.4.1. Calcitonin
5.4.2. Glucagon
CHAPTER 6. GLOBAL BIOSIMILARS MARKET – BY TYPE OF
MANUFACTURING
6.1 Introduction
6.2 In-house manufacturing
6.3 Contract manufacturing
CHAPTER 7. GLOBAL BIOSIMILARS MARKET - BY DISEASE
7.1. Introduction
7.2. Oncology
7.3. Autoimmune diseases
7.4. Blood disorders
7.5. Chronic diseases
7.6. Growth hormone deficiency
7.7. Infectious diseases
7.8. Other diseases
CHAPTER 8. GLOBAL BIOSIMILARS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL BIOSIMILARS MARKET - COMPANY PROFILES
9.1. Pfizer Inc.
9.2. Eli Lilly and Company
9.3. Celltrion Healthcare.
9.4. Mylan NV
9.5. Novartis AG.
9.6. Samsung Bioepis Co. Ltd.
9.7. Stada Arzneimittel AG.
9.8. Teva Pharmaceutical Industries Ltd.
9.9. Intas Biopharmaceuticals.
9.10. LG Life Sciences.
9.11. Johnson & Johnson.
9.12. Biocon Limited
9.13. Dong-A St.
9.14. Hospira Inc
9.15. Dr. Reddy’s Laboratories.
CHAPTER 10. GLOBAL BIOSIMILARS MARKET - COMPETITIVE LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
